# Nathanael S. Gray

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nathanael-s-gray/

## Facts

| Field | Value |
| --- | --- |
| Citations | 87,125 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 146 |
| i10-index | 525 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5022352605 |
| ORCID iD | https://orcid.org/0000-0001-5354-7403 |
| Works | 1,465 |

## Researcher papers

Showing 12 of 13.

- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation](https://scholariq.org/papers/cdk4-6-inhibition-augments-antitumor-immunity-by-enhancing-t-cell-activation/)
- [Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway](https://scholariq.org/papers/treatment-induced-tumor-dormancy-through-yap-mediated-transcriptional/)
- [Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer](https://scholariq.org/papers/mutations-in-the-i-ddr2-i-kinase-gene-identify-a-novel-therapeutic-target-in/)
- [A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader](https://scholariq.org/papers/a-chemoproteomic-approach-to-query-the-degradable-kinome-using-a-multi-kinase/)
- [Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?](https://scholariq.org/papers/exploration-of-type-ii-binding-mode-a-privileged-approach-for-kinase-inhibitor/)
- [Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials](https://scholariq.org/papers/synthesis-structure-activity-relationships-and-in-vivo-efficacy-of-the-novel/)
- [Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development](https://scholariq.org/papers/mapping-the-degradable-kinome-provides-a-resource-for-expedited-degrader/)
- [The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers](https://scholariq.org/papers/the-neuroblastoma-associated-f1174l-alk-mutation-causes-resistance-to-an-alk/)
- [Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors](https://scholariq.org/papers/reactivation-of-erk-signaling-causes-resistance-to-egfr-kinase-inhibitors/)
- [The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling](https://scholariq.org/papers/the-ikappab-kinase-family-phosphorylates-the-parkinson-s-disease-kinase-lrrk2-at/)
- [Rewiring cancer drivers to activate apoptosis](https://scholariq.org/papers/rewiring-cancer-drivers-to-activate-apoptosis/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways-2/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.